Mixed tauopathy refers to neurodegenerative diseases characterized by the pathological accumulation of both three-repeat (3R) and four-repeat (4R) tau protein isoforms. Unlike pure 3R tauopathies (such as Pick's disease) or pure 4R tauopathies (such as progressive supranuclear palsy and corticobasal degeneration), mixed tauopathies demonstrate pathology involving tau isoforms from both categories 1. This mixed pathology is most characteristically seen in Alzheimer's disease but also occurs in other conditions.
The human tau protein, encoded by the MAPT gene on chromosome 17q21.31, exists as six isoforms in the adult brain due to alternative splicing of exons 2, 3, and 10 [1]. These isoforms are classified based on the number of microtubule-binding repeats:
In the normal adult brain, there is an approximately equal ratio of 3R to 4R tau [2]. This balanced expression is critical for normal tau function in microtubule stabilization and axonal transport regulation.
Tau is primarily involved in [3]:
In disease states, tau becomes hyperphosphorylated, leading to [4]:
The structural differences between 3R and 4R tau isoforms arise from the alternative splicing of exon 10:
The inclusion of exon 10 adds an additional microtubule-binding repeat (R2), conferring enhanced microtubule binding affinity to 4R isoforms. This structural difference has important implications for disease pathogenesis and therapeutic targeting.
In mixed tauopathy, both 3R and 4R tau isoforms become pathologically modified and aggregate. This process involves: [5]
Neurofibrillary tangles are intracellular inclusions composed of paired helical filaments (PHFs) and straight filaments (SFs) of hyperphosphorylated tau. In Alzheimer's disease, NFTs contain both 3R and 4R tau isoforms [3:1]. The composition can vary by brain region and disease stage. [6]
In AD, neuritic plaques contain tau-positive dystrophic neurites surrounding amyloid-beta cores. These plaques show mixed tau isoform involvement and represent a combination of amyloid and tau pathologies. [7]
Soluble tau oligomers are considered the most toxic species in tauopathy. Both 3R and 4R tau can form oligomers, and mixed oligomers may have distinct toxic properties [4:1]. [8]
Alzheimer's disease (AD) is the classic mixed tauopathy, with neurofibrillary tangles containing both 3R and 4R tau [5:1]. Key features include: [9]
CTE resulting from repetitive traumatic brain injury shows mixed 3R/4R tau pathology, particularly in perivascular regions and at the depths of cortical sulci 7. The trauma-induced mechanism may affect both tau isoform populations.
Individuals with Down syndrome (TRIP21 trisomy 21) develop Alzheimer's-type pathology at an early age due to the extra copy of the APP gene. Their tau pathology shows mixed isoform involvement similar to sporadic AD 8.
ARTAG shows mixed tau isoform pathology in astrocytes, with both 3R and 4R tau in some cases. This recently characterized pathology is found in aging brains and various neurodegenerative diseases 9.
Multiple kinases contribute to tau hyperphosphorylation in mixed tauopathy:
Reduced activity of protein phosphatases (PP2A, PP1) contributes to tau hyperphosphorylation. PP2A accounts for approximately 70% of tau phosphatase activity in the brain 10.
The autophagy-lysosome and ubiquitin-proteasome systems are impaired in mixed tauopathy, leading to accumulation of both normal and modified tau species.
Tau pathology spreads through:
Beyond phosphorylation, multiple PTMs contribute to mixed tauopathy:
| Modification | Effect on Tau | Disease Relevance |
|---|---|---|
| Phosphorylation | Conformational change, reduced MT binding | Primary driver of pathology |
| Acetylation | Blocks degradation, promotes aggregation | Emerging therapeutic target |
| Truncation | Generates toxic fragments | 3R/4R specific patterns |
| Glycation | Cross-linking, aggregation | Age-related enhancement |
| SUMOylation | Alters subcellular localization | Regulatory mechanism |
The structure of tau fibrils differs between 3R and 4R containing fibrils:
The concept of "tau strains" suggests that different fibril structures may have different propagation properties and clinical phenotypes[10].
Multiple biomarker modalities inform the diagnosis of mixed tauopathy[11]:
Distinguishing mixed tauopathy from pure forms requires integration of clinical, imaging, and biomarker data[12]:
| Disease | Tau Isoform Pattern | Key Clinical Features | Biomarker Signature |
|---|---|---|---|
| Alzheimer's Disease | Mixed 3R/4R | Memory impairment, posterior cortical atrophy | Aβ+, p-tau+ |
| Pick's Disease | Pure 3R | Behavioral variant FTD | Aβ-, 3R+ |
| PSP | Pure 4R | Vertical gaze palsy, postural instability | 4R+, Aβ- |
| CBD | Pure 4R | Apraxia, cortical sensory loss | 4R+, Aβ- |
| AGD | Pure 4R | Amygdala predominant, late onset | 4R+, Aβ- |
| CTE | Mixed 3R/4R | History of TBI, mood changes | Variable Aβ |
Different patterns of mixed tau pathology correlate with distinct clinical presentations[13]:
Therapeutic strategies for mixed tauopathy span multiple mechanistic approaches:
Tau aggregation inhibitors: Target both 3R and 4R tau fibrils
Immunotherapy: Antibodies against common tau epitopes
Kinase inhibitors: Modulate multiple tau-phosphorylating enzymes
Microtubule stabilizers: Restore tau's normal function
Protein clearance enhancement: Promote autophagic and proteasomal degradation
The heterogeneity of tau isoforms in mixed tauopathy presents unique challenges:
Mixed tauopathy represents a common pattern of tau pathology in neurodegenerative diseases, with Alzheimer's disease as the prototypical example. The coexistence of 3R and 4R tau isoforms in neurofibrillary tangles reflects the complex molecular pathogenesis of these disorders. Understanding the mechanisms underlying mixed tau pathology is essential for developing effective therapies targeting tau accumulation and spreading. The integration of biomarker-based diagnosis, isoform-specific therapeutic approaches, and early intervention strategies offers the most promising path forward for addressing this challenging aspect of neurodegeneration.
Hutton M, Lendon CL, Rizzu P, et al. MAPT mutations and tau isoforms. Nature. 2002. ↩︎
Ballatore C, Lee VM, Trojanowski JQ. Tau phosphorylation in neurodegeneration. Nat Rev Neurosci. 2012. ↩︎
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Tau pathology in AD: clinicopathologic correlations. J Neuropathol Exp Neurol. 2013. ↩︎ ↩︎
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, et al. Tau oligomers as toxic species. J Neurosci. 2014. ↩︎ ↩︎
Kelley BJ, Boeve BF, Josephs KA. Frontotemporal tauopathies classification. Nat Rev Neurol. 2012. ↩︎ ↩︎
McKee AC, Cantu RC, Hedley-Whyte ET, et al. CTE tau pathology. J Neuropathol Exp Neurol. 2017. ↩︎
Cataldo AM, Petanceska S, Peterhoff CM, et al. Tauopathy in Down syndrome. Acta Neuropathol. 2012. ↩︎
Kovacs GG, Roggendorf W, et al. Aging-related tau astrogliopathy. Acta Neuropathol. 2015. ↩︎
Bancher C, Brunner C, Lassmann H, et al. Tau phosphatases. J Neural Transm Suppl. 2012. ↩︎
Dickinson PJ, Knopman DS, et al. Neurodegenerative disease taxonomy. Brain. 2018. ↩︎
Growdon JH, Schultz AP, et al. Biomarkers and prodromal AD. Nat Rev Neurol. 2018. ↩︎
Murray ME, Dickson DW. Neuropathological criteria for Alzheimer's disease. Acta Neuropathol. 2017. ↩︎
Seeley WW, Crawford R, et al. Alzheimer disease phenotypes. Neurology. 2009. ↩︎